SmallCapFirm
Up Approximately 10%, Nasdaq Breakout Idea (BNOX) Is Running Green With Backing From Last Night's Huge News
March 9th
SCF Readers,
BNOX is surging green. Watching?
Dropping news last evening, BNOX has hit the ground running and is currently up approximately 10% after hitting an early high of $5.15 this morning.
Could more be on the way?
Check out the news here:
Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)
- Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challenge
- Results achieved statistical significance in post-hoc analysis of the full data set and in relevant subpopulations
- Favourable safety, tolerability and PK findings are consistent with a fast-acting non-sedating anxiolytic profile
- The company is planning an End of Phase 2 (EoPh2) meeting to discuss BNC210’s late-stage SAD program 2H 2023
- Webcast and conference call scheduled for Thursday, March 9, 2023 at 8:00 AM EST (Friday, March 10, 2023 at 12:00 AM AEDT)
ADELAIDE, Australia, March 08, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel allosteric ion channel modulators for serious central nervous system (CNS) disorders with high unmet medical need, today announced the release of a comprehensive analysis of the data from its Phase 2 PREVAIL study to evaluate the efficacy and safety of BNC210, a novel α7 nicotinic acetylcholine receptor negative allosteric modulator, for the acute treatment of Social Anxiety Disorder (SAD). These data support late-stage development of BNC210 in SAD.
...
“PREVAIL revealed BNC210’s potential as a non-sedating anxiolytic for the acute treatment of SAD. These results follow positive findings in a panic attack model and in patients with generalized anxiety disorder, further support clinical proof of concept in anxiety disorders and de-risk BNC210’s continuing development,” remarked Spyros Papapetropoulos MD, PhD, President and Chief Executive Officer of Bionomics. “We look forward to meeting with the FDA in the coming months to discuss our clinical path forward for this exciting new therapeutic candidate.”
“The full analysis of the data indicates that patients receiving BNC210 show reduced distress compared to placebo. Given the observed effect size in PREVAIL, there is reason to believe that a subsequent trial with a larger sample size could achieve its primary endpoint,” commented Dr. Murray Stein, MD, MPH. Dr. Stein continued, “The finding that a statistically significant separation from the placebo occurred when the two dose levels and the anticipation and performance phases were combined is important. Both anticipation and performance are very relevant to understand clinically, so there would be a lot of value in combining these phases as a key data output in future trials.”
Read the full article here.
On top of this awesome news is BNOX trades above multiple lines of potential support.
And with a 200-Day Simple Moving Average over $7.00, there could be significant room for BNOX to move vertically before running into potential resistance.
Drop everything and get BNOX on radar now.
-----
Let's dive in with a quick recap.
For Tuesday's opening bell, I delivered a new Nasdaq breakout idea.
Making a strong 2-day surge from an open of $1.61 to a $1.90 high, it put together an approximate 18% move which may only be the start.
It'll be important to keep it on radar because the last 2 times I alerted it, it ran big over the span of a few weeks.
But in the meantime, we need to focus on another Nasdaq breakout idea.
This company is aiming their focus at large underserved markets with over 25 million patients in the US alone suffering from Social Anxiety Disorder ("SAD") and Post Traumatic Stress Disorder ("PTSD").
To put it in perspective, the global SAD treatment market size is projected to reach $13.9Bn by 2027 while the PTSD treatment market size is projected to reach $26.1Bn by 2031.
And with the alarmingly high frequency of anxiety and sadness around the world from recent difficulties stemming from the pandemic and more, they may be in the right space at the right time to create a treatment that could utterly be game-changing (globally).
Based on a float of fewer than 6Mn shares, an explosive chart history with multiple $1.00+ intraday moves, a new CEO/President in charge, and it closed above multiple lines of potential support Wednesday, this Nasdaq Biopharma profile could be a ripe breakout target.
For Thursday, March 9th, this profile requires immediate attention:
Bionomics Limited (BNOX)
Bionomics is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD).
Beyond BNC210, Bionomics has a strategic partnership with Merck & Co, Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
And based on several potential catalysts, BNOX could become a near term breakout target. Check them out:
No. 1 - Low Float Could Provide Significant Volatility Potential On Daily Basis
No. 2 - An Explosive Chart History With Several Massive Intraday Rips
No. 3 - New President/CEO Is Critical Milestone For The Leadership Team
No. 4 - Could Momentum Be Building? BNOX Closes Wednesday Above Key Lines Of Potential Support
But more on those in a second...
BNOX's Focused CNS Pipeline
Bionomics is developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need.
Ion channels serve as important mediators of physiological function in the CNS and the modulation of ion channels influences neurotransmission that leads to downstream signaling in the brain.
The α7 nicotinic acetylcholine (“ACh”) receptor (“α7 receptor”) is an ion channel that plays an important role in driving emotional responses and cognitive performance.
Utilizing their expertise in ion channel biology and translational medicine, they are developing orally active small molecule negative allosteric modulators (“NAMs”) and positive allosteric modulators (“PAMs”) of the α7 receptor to treat anxiety and stressor-related disorders and cognitive dysfunction, respectively.
